Novogen Limited (NASDAQ: NVGN) shares galloped 8% to $2.92. The company disclosed that the Food and Drug Administration has approved the Investigational New Drug application for Cantrixil in patients with ovarian cancer. Share volume was 636,000, triumphing over an all-day average of 32,000
